Adaptive Radiation Therapy for Prostate Cancer

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

Recruiting N/A Interventional Study
Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Male
Study type
Interventional
Purpose
Treatment
Participants needed
132 (estimated)
Sponsor
Varian, a Siemens Healthineers Company · Industry
Who this trial is looking for

This trial is looking for men with low to intermediate risk prostate cancer. Participants will receive a special type of radiation therapy aimed at reducing urinary side effects.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with prostate cancer that is low or intermediate risk.
  • I have a prostate volume of 80cc or less.
  • I have an AUA/IPSS score of 15 or less.
  • I am 18 years or older.
  • I am able to complete questionnaires.
  • I can understand and sign an informed consent form.

You may not be able to join if

  • I have severe gastrointestinal or urinary problems.
  • I have had prior pelvic radiotherapy.
  • I have had surgery on my prostate.
  • I have prostate cancer that has spread to nearby lymph nodes.
  • I have an active inflammatory bowel disease.
  • I cannot undergo a prostate MRI.
  • I cannot have fiducial markers placed in my prostate.
  • I am currently receiving chemotherapy.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patient has NCCN low or intermediate risk prostate cancer that is biopsy proven. 2. Prostate volume is ≤80cc as assessed by MRI prior to radiotherapy. 3. AUA/IPSS score is ≤ 15. 4. ECOG performance status is ≤2 (or Karnofsky score is ≥60%). 5. Patient has no PIRADS 4 or 5 les…
Contacts

Sean Davidson, MASc

1-437-991-8294

sean.davidson@siemens-healthineers.com

CONTACT

Claire McCann, PhD

claire.mccann@siemens-healthineers.com

CONTACT